Alternatives to TrakGene: a 2026 field guide for clinical pedigree software

Looking for an alternative to TrakGene? Here's an honest field guide. TrakGene is a credible modern clinical genetics platform — clinician-built, HL7 FHIR-first, with public customers including NIH, NHS services, and Geisinger. Most teams who reach this page are not dissatisfied with TrakGene as a clinical product; they are usually evaluating it alongside one or two modern peers, or looking for AI-assisted interpretation, richer cancer-risk modelling, or a lower-friction procurement path before making a decision.

This page covers four serious alternatives — Phenotips, FamGenix, Progeny, and Evagene — and tells you plainly where each fits and where each falls short. Evagene publishes this site; we mark its limitations (cancer-risk breadth against FamGenix, HPO against Phenotips) as plainly as we mark its strengths.

Short version. If HPO phenotyping is central, Phenotips. If cancer-risk breadth (BOADICEA v6, Tyrer-Cuzick v8, Gail, Claus, QRISK3) is central, FamGenix. If you want continuity with a long-established enterprise vendor, Progeny. If you want a modern peer to TrakGene with AI interpretation, an MCP server, Analysis Templates, and free Alpha access, Evagene.

Why teams look for alternatives to TrakGene

The most common reason is procurement. TrakGene does not publish list pricing; evaluation requires a sales conversation. For services that have already budgeted a platform and can run a procurement process, this is not an obstacle. For smaller teams, private counselling practices, or research groups who want to validate fit on a real case before opening a budget, a free or Alpha tier is often a practical necessity. Alternatives that publish pricing, run free tiers, or ship Alpha programmes remove the friction that TrakGene's enterprise sales motion introduces.

The second reason is modernising beyond FHIR. TrakGene's FHIR integration is strong, but AI-assisted interpretation, bring-your-own-key LLM support, Model Context Protocol agents, and programmatic pedigree tools are not among its publicly advertised features. Services whose 2026 roadmap includes AI-drafted reports, AI agents that need to read and analyse pedigrees, or embeddable pedigree viewers for patient portals often find it easier to build on a platform where those surfaces are first-class. A third reason is cancer-risk model breadth: TrakGene does not publicly advertise BOADICEA v6 or Tyrer-Cuzick v8, which services focused on breast and ovarian risk assessment may need.

Four alternatives worth evaluating

Phenotips

Phenotips is an enterprise-grade Genomic Health Record platform with Human Phenotype Ontology at its core. With 100,000+ records across 60+ countries per its homepage, it is a major player in institutional clinical genetics, particularly for undiagnosed rare disease services and phenotype-driven gene suggestion.

Where Phenotips fits as a TrakGene alternative: services whose workflow is HPO-first rare disease diagnostics rather than pedigree-first clinical genetics. Where it falls short: Phenotips and TrakGene share the enterprise sales-led procurement model, so Phenotips does not solve the pricing-opacity problem. If the thing that matters about your TrakGene evaluation is HPO depth, Phenotips is the stronger candidate. See our Phenotips vs Evagene article for detail.

FamGenix

FamGenix stands out for simultaneous coverage of BOADICEA v6, Tyrer-Cuzick v8, Gail, Claus, and QRISK3 — a combination matched by few products. It offers a free Individual tier and tiered pricing that removes enterprise procurement friction. For services whose practice is dominated by hereditary cancer risk assessment, it is a strong alternative.

Where FamGenix falls short relative to TrakGene: it is not positioned as a broad clinical genetics platform with FHIR-first EHR integration. If your service uses TrakGene for cardiac genetics, reproductive genetics, or integrated cohort work, FamGenix is likely narrower than you need.

Progeny

Progeny is among the longest-established clinical pedigree vendors (its product history reaches back to 1996) and has a real footprint in institutional clinical genetics. Its core strength is longevity, proven clinical deployments, and a mature feature set.

Where Progeny fits: institutions that want continuity with an established enterprise vendor and that value track record heavily. Where it falls short: third-party reports cite rising pricing over recent renewal cycles and an architectural heritage that predates modern cloud patterns. For teams choosing TrakGene over Progeny specifically because they wanted a modern architecture, Progeny is not a natural alternative; if the TrakGene evaluation concluded you want something even more enterprise-heavy, Progeny becomes worth considering.

Evagene

Evagene is a modern, browser-first clinical pedigree platform with the same modern-architecture emphasis that makes TrakGene attractive, but a different shape. Clinically it covers gesture-driven pedigree drawing with NSGC/ISCN standard notation, a 200+ disease catalogue annotated with ICD-10 and OMIM, BRCAPRO, MMRpro, and PancPRO from the BayesMendel suite, Mendelian inheritance calculators for AD, AR, and XR conditions, batch risk screening, a karyogram viewer, and consanguinity detection via Wright's coefficient.

What differentiates Evagene from TrakGene is the AI and platform surface. AI clinical interpretation uses bring-your-own-key (BYOK) LLMs for Anthropic Claude and OpenAI GPT — your service's clinical text flows to a provider you have already risk-assessed, not through a vendor-hosted model. Analysis Templates codify a house style for AI-drafted reports. The MCP server exposes 11 pedigree tools to Claude Desktop, Claude Code, and other MCP-compatible agents — so a clinician can ask their AI assistant to read, modify, or analyse a pedigree from inside their normal AI workspace. The REST API (scoped, rate-limited), HMAC-SHA256 webhooks, and the embeddable pedigree viewer (iframe/SVG/JS) cover the integration ground TrakGene addresses through FHIR, though with a more generic API-first shape.

Where Evagene falls short: it does not advertise the HL7 FHIR-native posture that is one of TrakGene's strongest positioning claims (FHIR support is available via the REST API rather than a first-class resource model). It does not currently include BOADICEA or Tyrer-Cuzick. It is in Alpha, with free access via waiting list; formal certifications should be confirmed at contract time. For teams evaluating TrakGene who want an AI-and-agent-first peer, Evagene is the intended fit.

Feature comparison matrix

Compiled from publicly available product pages as of April 2026. "—" means not publicly advertised.

How to choose

HPO-first rare disease. Phenotips remains the strongest fit; TrakGene and Evagene are both pedigree-first rather than HPO-first.

Cancer-risk-dominated practice. FamGenix for BOADICEA/Tyrer-Cuzick breadth; Evagene for BRCAPRO/MMRpro/PancPRO plus Mendelian.

Deep FHIR-native EHR integration. TrakGene leads; Evagene covers the ground through a generic REST API rather than a FHIR resource model. If FHIR-as-the-data-model matters, TrakGene is the more direct fit.

Modern AI, agents, and programmability. Evagene — BYOK LLM, MCP server, Analysis Templates, REST API, webhooks, embeddable viewer. Start free on Alpha via the waiting list.

Frequently asked questions

Further reading

• Phenotips vs Evagene: a detailed comparison
• Progeny vs Evagene
• Clinical genetics pedigree tools: a field guide
• Hereditary cancer risk assessment
• Pedigree drawing software
• The Evagene platform layer (API, MCP, webhooks)